A logo sits on display outside the offices of Aspen Pharmacare Holdings Ltd. in Durban, South Africa, on Tuesday, July 19, 2016. "Aspen believes absolutely that it can expand quickly into a market such as China, because the critical thing when it comes to medicine besides the price point is quality of the product," Stephen Saad, chief executive officer of Aspen Pharmacare Holdings Ltd., said. Photographer: Waldo Swiegers/Bloomberg

The inside story from Aspen on Covid-19 dexamethasone: MUST LISTEN

Aspen group senior executive Stavros Nicolaou shares details of what is known about Covid-19 life-saving drug Dexamethasone and supply arrangements with BizNews founder Alec Hogg.

Published on:

18 Jun 2020, 7:40 am

This week, the world woke up to the exciting news that dexamethasone, a cheap drug in the Aspen stable, dramatically improves the chances of survival for people seriously ill in hospitals with Covid-19. The Aspen share price has jumped up in value on the Johannesburg Stock Exchange as investors anticipate high demand for dexamethasone. In this interview with BizNews founder Alec Hogg, Aspen group senior executive Stavros Nicolaou shares the details of what is known about Dexamethasone and how it will be made available. – Editor

There was lots of action on the Johannesburg Stock Exchange today for Aspen, the pharmaceutical company that dominates the South African sector. And that's because of a drug called dexamethasone. Stavros Nicolaou is the senior executive of strategic trade for Aspen.

___STEADY_PAYWALL___

Loading content, please wait...

Covid-19

Aspen

remdesivir

Stavros Nicolaou

Dexamethasone

The inside story from Aspen on Covid-19 dexamethasone: MUST LISTEN

Related Stories